Adults with Attention Deficit Hyperactivity Disorder (ADHD) are more likely to smoke and find it difficult to quit smoking.
ADHD is a neurological developmental disorder that affects children and adults, characterized mainly by symptoms of inattention and hyperactivity. The US Food and Drug Administration (FDA) explains that nicotine can alter brain function, leading to nicotine addiction and smoking dependency.
Medical News Today explains that the stimulating effects of nicotine may help improve the attention of individuals with ADHD, suggesting that nicotine may aid in controlling their symptoms.
Meanwhile, a recently published study in the British Medical Journal (BMJ) emphasizes that smokers with mental illnesses are underrepresented in clinical trials for smoking cessation. Data consistently shows that individuals with mental illnesses are more likely to smoke than non-smokers, making it crucial to include them in clinical trials related to quitting smoking. Unfortunately, the opposite seems to be true.
People with mental health disorders who smoke are excluded from smoking cessation clinical trials. The headline is "Inequality in Smoking Cessation Clinical Trials Testing Drug Therapies: Excluding Smokers with Mental Health Disorders." This commentary aims to examine the practice and reasons behind excluding smokers with mental health disorders (MHD) from such clinical trials.
A research team has analyzed the Cochrane systematic review database up to September 2020 to obtain an evaluation of drug therapy for smoking cessation. "We included 279 randomized controlled trials from 13 Cochrane reviews. In all studies, 51 (18.3%) explicitly excluded participants with any mental health disorders, 152 (54.5%) conditionally excluded them based on certain mental health disorder criteria, and 76 (27.2%) provided insufficient information to determine inclusion or exclusion. The study found that, compared to nicotine replacement therapy studies, studies on antidepressant drugs used for smoking cessation were 3.33 times more likely to conditionally exclude smokers with mental health disorders (95% CI 1.38 to 8.01, p=0.007)," the researchers reported.
In fact, their conclusion was that there were not enough participants with MHD (mental health disorders) in clinical trials testing the safety and efficacy of smoking cessation drugs, and there was not enough data collected to explain why. The study highlights the importance of promoting participation from this minority group in trials.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
